Sequana

Sequana Medical wins Best Technology Award for alfapump® at European Mediscience Awards

Retrieved on: 
Friday, June 16, 2023

Ghent, Belgium – 16 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that its alfapump has won the ‘Best Technology’ Award at the European Mediscience Awards in London last night.

Key Points: 
  • Ghent, Belgium – 16 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that its alfapump has won the ‘Best Technology’ Award at the European Mediscience Awards in London last night.
  • The European Mediscience Awards event is the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe.
  • Bringing together the best of European mediscience companies to celebrate achievement and recognise success, its awards are hotly contested.
  • The recognition of this work by our industry peers is a tremendous accolade for the Sequana team and celebrates all the hard work that has gone into developing this transformational device.”

Global Supercomputers Market (2022 - 2027): Increasing Demand for Higher Processing Power to Drive the Market Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 17, 2022

The Supercomputers Market is expected to register a CAGR of about 9.49% during the forecast period 2022 - 2027.

Key Points: 
  • The Supercomputers Market is expected to register a CAGR of about 9.49% during the forecast period 2022 - 2027.
  • This increasing demand for higher processing power for managing data and decision-making drives the studied market.
  • Further, many government bodies are investing in research works for high-end projects that drive the supercomputers market.
  • The supercomputers market is consolidated due to a few major players holding a greater share of the market.

Sequana Medical announces first patient enrolled in SAHARA DESERT

Retrieved on: 
Tuesday, June 1, 2021

Secondary feasibility endpoints include the ability of DSR therapy to restore and maintain euvolemia without the need for additional loop diuretic treatment.

Key Points: 
  • Secondary feasibility endpoints include the ability of DSR therapy to restore and maintain euvolemia without the need for additional loop diuretic treatment.
  • Sequana Medical has combined its proven alfapump and proprietary DSR therapy, and is developing the alfapump DSR, a breakthrough approach to fluid overload due to heart failure.
  • These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially.
  • You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.

Sequana Medical Announces Annual and Extraordinary General Meetings of Shareholders on 27 May 2021

Retrieved on: 
Tuesday, April 27, 2021

The U.S. market for the alfapump resulting from NASH-related cirrhosis is forecast to exceed \xe2\x82\xac3 billion annually within the next 10-20 years.

Key Points: 
  • The U.S. market for the alfapump resulting from NASH-related cirrhosis is forecast to exceed \xe2\x82\xac3 billion annually within the next 10-20 years.
  • Interim data from the ongoing North American pivotal study (POSEIDON) showed positive outcomes against all primary endpoints of the study.
  • Building on its proven alfapump platform, Sequana Medical is developing the alfapump DSR, a breakthrough, proprietary approach to fluid overload due to heart failure.
  • You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.\n"

Sequana Medical announces Annual and Extraordinary General Meetings of Shareholders on 27 May 2021

Retrieved on: 
Tuesday, April 27, 2021

The U.S. market for the alfapump resulting from NASH-related cirrhosis is forecast to exceed \xe2\x82\xac3 billion annually within the next 10-20 years.

Key Points: 
  • The U.S. market for the alfapump resulting from NASH-related cirrhosis is forecast to exceed \xe2\x82\xac3 billion annually within the next 10-20 years.
  • Interim data from the ongoing North American pivotal study (POSEIDON) showed positive outcomes against all primary endpoints of the study.
  • Building on its proven alfapump platform, Sequana Medical is developing the alfapump DSR, a breakthrough, proprietary approach to fluid overload due to heart failure.
  • You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.\n"

Sequana Medical Notice of 2020 Full Year Results and Business Update

Retrieved on: 
Wednesday, March 10, 2021

Interim data from the ongoing North American pivotal study (POSEIDON) showed positive outcomes against all primary endpoints of the study.

Key Points: 
  • Interim data from the ongoing North American pivotal study (POSEIDON) showed positive outcomes against all primary endpoints of the study.
  • Building on its proven alfapump platform, Sequana Medical is developing the alfapump DSR, a breakthrough, proprietary approach to fluid overload due to heart failure.
  • These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially.
  • You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.

Sequana Medical Notice of 2020 Full Year Results and Business Update

Retrieved on: 
Wednesday, March 10, 2021

Interim data from the ongoing North American pivotal study (POSEIDON) showed positive outcomes against all primary endpoints of the study.

Key Points: 
  • Interim data from the ongoing North American pivotal study (POSEIDON) showed positive outcomes against all primary endpoints of the study.
  • Building on its proven alfapump platform, Sequana Medical is developing the alfapump DSR, a breakthrough, proprietary approach to fluid overload due to heart failure.
  • These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially.
  • You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.

Sequana Medical to present at Jefferies 2020 Virtual London Healthcare Conference

Retrieved on: 
Thursday, November 12, 2020

The U.S. market for the alfapump resulting from NASH-related cirrhosis is forecast to exceed 3 billion annually within the next 10-20 years.

Key Points: 
  • The U.S. market for the alfapump resulting from NASH-related cirrhosis is forecast to exceed 3 billion annually within the next 10-20 years.
  • Both indications leverage Sequana Medical's alfapump, a unique, fully implanted wireless device that automatically pumps fluid from the abdomen into the bladder, where it is naturally eliminated through urination.
  • Building on its proven alfapump platform, Sequana Medical is developing the alfapump DSR, a breakthrough, proprietary approach to fluid overload due to heart failure.
  • You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.

Sequana Medical to present at Jefferies 2020 Virtual London Healthcare Conference

Retrieved on: 
Thursday, November 12, 2020

The U.S. market for the alfapump resulting from NASH-related cirrhosis is forecast to exceed 3 billion annually within the next 10-20 years.

Key Points: 
  • The U.S. market for the alfapump resulting from NASH-related cirrhosis is forecast to exceed 3 billion annually within the next 10-20 years.
  • Both indications leverage Sequana Medical's alfapump, a unique, fully implanted wireless device that automatically pumps fluid from the abdomen into the bladder, where it is naturally eliminated through urination.
  • Building on its proven alfapump platform, Sequana Medical is developing the alfapump DSR, a breakthrough, proprietary approach to fluid overload due to heart failure.
  • You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.

Sequana Medical Appoints Two Additional Experts as Heart Failure Scientific Advisors

Retrieved on: 
Thursday, October 15, 2020

GHENT, Belgium, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces the appointments of Dr. Michael Felker and Dr. James Udelson as new Heart Failure Scientific Advisors.

Key Points: 
  • GHENT, Belgium, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces the appointments of Dr. Michael Felker and Dr. James Udelson as new Heart Failure Scientific Advisors.
  • They join current advisors Dr. Javed Butler, Dr. Maria Rosa Costanzo, Dr. Wilson Tang and Dr. Jeffrey Testani as Heart Failure Scientific Advisors to Sequana Medical .
  • The Sequana Medical management team is working closely with its advisors on the development of alfapump DSR (Direct Sodium Removal).
  • Built on its proven alfapump platform, alfapump DSR is Sequana Medicals breakthrough approach for the management of fluid overload in patients suffering from heart failure.